CDKL5 deficiency disorder

Ovid drug reduces seizure frequency in two rare forms of epilepsy, according to early Phase II data

The data from a Phase II pilot and an extension study of soticlestat, also known as OV935 or TAK-935, showed short- and long-term reductions of seizure frequency in patients with CDKL5 deficiency disorder and Dup15q syndrome.

By Alaric DeArment

BioPharma, Policy

Marinus scores in Phase III genetic epilepsy drug study, wins BARDA contract for IV formulation

The company announced a contract with BARDA to develop intravenous ganaxolone for a seizure disorder that can result from exposure to nerve agents, in addition to announcing successful results from its Phase III trial of the oral version of the drug in a CDKL5 deficiency disorder, or CDD.

By Alaric DeArment

Closing the Quality-Affordability Gap in Workplace Mental Health

In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.

By Stephanie Baum

The Healthcare Payments Industry Faces a Perception Challenge

Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.

By Lisa Brooks, Vice President, Healthcare Partnerships

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah